Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
about
Pharmacotherapy of 'treatment resistant' type 2 diabetes.Enhancing the therapeutic potential of peptide toxins.Liraglutide for weight management: benefits and risks.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.Obesity and Cancer: Existing and New Hypotheses for a Causal Connection.
P2860
Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
@en
type
label
Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
@en
prefLabel
Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
@en
P2093
P2860
P1476
Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
@en
P2093
Brian Tomlinson
Yuzhen Zhang
Zhong-Min Liu
P2860
P304
P356
10.1080/13543784.2016.1221925
P407
P577
2016-08-26T00:00:00Z